The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8 hinge region, a CD8 transmembrane region, a 4-1BB co-stimulatory domain and a CD3 signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

Provided herein are antibodies that specifically bind to MICA/B having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions disclosed herein, as well as methods and uses thereof

A local pharmaceutical composition includes a probiotic component. The probiotic component can be included as an active ingredient for the treatment of local lesion diseases. The local composition provides a unique pharmacology that realizes chemical ablation-like local treatment and achieves a local effect (or local synergy) and/or immunotherapy. The immunotherapy includes a secondary immunological effect associated with the local effect (or local synergy), which cannot be achieved by existing probiotic compositions. The local composition has almost completely non-toxic systemic safety and a significantly higher long-term efficacy than other compositions. The composition can treat rapidly growing tumors, large tumors and hypovascular tumors, and is absent of drug resistance. The composition is convenient to prepare and has low costs.

The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

This disclosure relates to dosage regimens for targeted TGF- inhibition with a bi-functional fusion protein for use in a method of treating biliary tract cancer or inhibiting biliary tract tumor growth in treatment nave patients, or patients with locally advanced or metastatic BTC who have failed or are intolerant to first-line systemic chemotherapy.

Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.

Methods and compositions for treating primary hepatic cancers and/or secondary hepatic cancers using a combination of talimogene laherparepvec and pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present disclosure provides a method for treating HCC comprising co-administering to the patient, dendritic cells-based vaccine in combination with an immune checkpoint inhibitor. The treatment with DC vaccine in combination with immune checkpoint inhibitor has significantly improved overall survival in subjects.